Pharmacologic and complementary and alternative medicine therapies for irritable bowel syndrome

Gut and Liver

Volumn 5, Issue 3, 2011, Pages 253-266

  Chey, William D ^a   Maneerattaporn, Monthira ^b   Saad, Richard ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b MAHIDOL UNIVERSITY   (Thailand)

Author keywords

Antibiotics; Antidepressants; Chloride secretogogues; Probiotics; Serotonin

Indexed keywords

ALOSETRON; ANTIBIOTIC AGENT; ANTIDEPRESSANT AGENT; ANTIDIARRHEAL AGENT; ASIMADOLINE; AST 120; CENTRAL STIMULANT AGENT; CHENODEOXYCHOLIC ACID; CROFELEMER; EMICERFONT; ISPAGULA; ITOPRIDE; LAXATIVE; LINACLOTIDE; LOPERAMIDE; LUBIPROSTONE; MACROGOL; MOSAPRIDE CITRATE; OSMOTIC AGENT; PEXACERFONT; PLECANATIDE; PROBIOTIC AGENT; PROKINETIC AGENT; PRUCALOPRIDE; PUMOSETRAG; RAMOSETRON; RIFAXIMIN; SPASMOLYTIC AGENT; TEGASEROD; UNINDEXED DRUG;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ACUPUNCTURE; ALTERNATIVE MEDICINE; BACTERIAL OVERGROWTH; BLOATING; CHRONIC DISEASE; CLINICAL EFFECTIVENESS; COLON ISCHEMIA; CONSTIPATION; DIARRHEA; DIET SUPPLEMENTATION; DIET THERAPY; DIETARY FIBER; DISTRESS SYNDROME; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; HERBAL MEDICINE; HUMAN; HYPERSENSITIVITY; INTESTINE FLORA; INTESTINE MOTILITY; INTESTINE TRANSIT TIME; IRRITABLE COLON; ISCHEMIC COLITIS; MONOTHERAPY; NAUSEA; NONHUMAN; REVIEW; TREATMENT RESPONSE; VISCERA;

EID: 80052427809     PISSN: 19762283     EISSN: None     Source Type: Journal    
DOI: 10.5009/gnl.2011.5.3.253     Document Type: Review

References (140)

1. Longstreth G.F., Thompson W.G., Chey W.D., Houghton L.A., Mearin F., Spiller R.C. Functional bowel disorders. Gastroenterology 2006;130:1480-1491.
2. Longstreth G.F., Wilson A., Knight K., et al. Irritable bowel syndrome,health care use, and costs: A U.S. managed care perspective. Am J Gastroenterol 2003;98:600-607. (Pubitemid 36348532)
3. Hungin A.P., Chang L., Locke G.R., Dennis E.H., Barghout V. Irritable bowel syndrome in the United States: Prevalence, symptom patterns and impact. Aliment Pharmacol Ther 2005;21:1365-1375. (Pubitemid 40813683)
4. Grundmann O., Yoon S.L. Irritable bowel syndrome: epidemiology, diagnosis and treatment: an update for health-care practitioners. J Gastroenterol Hepatol 2010;25:691-699.
5. El-Serag H.B., Olden K., Bjorkman D. Health-related quality of life among persons with irritable bowel syndrome: A Systematic review. Aliment Pharmacol Ther 2002;16:1171-1185. (Pubitemid 34680762)
6. Gralnek I.M., Hays R.D., Kilbourne A., Naliboff B., Mayer E.A. The impact of irritable bowel syndrome on health-related quality of life. Gastroenterology 2000;119:654-660.
7. Crowell M.D., Harris L., Jones M.P., Chang L. New insights into the pathophysiology of irritable bowel syndrome: Implications for future treatments. Curr Gastroenterol Rep 2005;7:272-279. (Pubitemid 41223339)
8. Hasler W.L. Traditional thoughts on the pathophysiology of irritable bowel syndrome. Gastroenterol Clin North Am 2011;40:21-43.
9. Ohman L., Simrén M. Pathogenesis of IBS: role of inflammation, immunity and neuroimmune interactions. Nat Rev Gastroenterol Hepatol 2010;7:163-173.
10. Pimentel M., Chang C. Inflammation and microflora. Gastroenterol Clin North Am 2011;40:69-85.
11. Manabe N., Wong B.S., Camilleri M., Burton D., McKinzie S., Zinsmeister A.R. Lower functional gastrointestinal disorders: evidence of abnormal colonic transit in a 287 patient cohort. Neurogastroenterol Motil 2010;22:293-e82.
12. Deiteren A., Camilleri M., Burton D., McKinzie S., Rao A., Zinsmeister A.R. Effect of meal ingestion on ileocolonic and colonic transit in health and irritable bowel syndrome. Dig Dis Sci 2010;55:384-391.
13. Lee O.Y. Asian motility studies in irritable bowel syndrome. J Neurogastroenterol Motil 2010;16:120-130.
14. Chey W.Y., Jin H.O., Lee M.H., Sun S.W., Lee K.Y. Colonic motility abnormality in patients with irritable bowel syndrome exhibiting abdominal pain and diarrhea. Am J Gastroenterol 2001;96:1499-1506. (Pubitemid 32455081)
15. Ritchie J. Pain from distension of the pelvic colon by inflating a balloon in the irritable colon syndrome. Gut 1973;14:125-132.
16. Whitehead W.E., Holtkotter B., Enck P., et al. Tolerance for rectosigmoid distention in irritable bowel syndrome. Gastroenterology 1990;98(5 Pt 1):1187-1192. (Pubitemid 20143101)
17. Mertz H., Naliboff B., Munakata J., Niazi N., Mayer E.A. Altered rectal perception is a biological marker of patients with irritable bowel syndrome. Gastroenterology 1995;109:40-52.
18. Nozu T., Kudaira M., Kitamori S., Uehara A. Repetitive rectal painful distention induces rectal hypersensitivity in patients with irritable bowel syndrome. J Gastroenterol 2006;41:217-222.
19. Spiller R.C. Potential biomarkers. Gastroenterol Clin North Am 2011;40:121-139.
20. Zhou Q., Fillingim R.B., Riley J.L. 3rd, Malarkey W.B., Verne G.N. Central and peripheral hypersensitivity in the irritable bowel syndrome. Pain 2010;148:454-461.
21. Tillisch K., Mayer E.A., Labus J.S. Quantitative meta-analysis identifies brain regions activated during rectal distension in irritable bowel syndrome. Gastroenterology 2011;140:91-100.
22. Drossman D.A. Do psychosocial factors define symptom severity and patient status in irritable bowel syndrome? Am J Med 1999;107(5A):41S-50S.
23. Ohman L., Simrén M. New insights into the pathogenesis and pathophysiology of irritable bowel syndrome. Dig Liver Dis 2007;39:201-215. (Pubitemid 46196435)
24. Garvin B., Wiley J.W. The role of serotonin in irritable bowel syndrome: implications for management. Curr Gastroenterol Rep 2008;10:363-368.
25. Houghton L.A., Atkinson W., Whitaker R.P., Whorwell P.J., Rimmer M.J. Increased platelet depleted plasma 5-hydroxytryptamine concentration following meal ingestion in symptomatic female subjects with diarrhoea predominant irritable bowel syndrome. Gut 2003;52:663-670. (Pubitemid 36528867)
26. Dunlop S.P., Coleman N.S., Blackshaw E., et al. Abnormalities of 5-hydroxytryptamine metabolism in irritable bowel syndrome. Clin Gastroenterol Hepatol 2005;3:349-357. (Pubitemid 40488343)
27. Atkinson W., Lockhart S., Whorwell P.J., Keevil B., Houghton L.A. Altered 5-hydroxytryptamine signaling in patients with constipation-and diarrhea-predominant irritable bowel syndrome. Gastroenterology 2006;130:34-43. (Pubitemid 43049833)
28. Thabane M., Marshall J.K. Post-infectious irritable bowel syndrome. World J Gastroenterol 2009;15:3591-3596.
29. Halvorson H.A., Schlett C.D., Riddle M.S. Postinfectious irritable bowel syndrome: a meta-analysis. Am J Gastroenterol 2006;101:1894-1899.
30. Marshall J.K., Thabane M., Borgaonkar M.R., James C. Postinfectious irritable bowel syndrome after a food-borne outbreak of acute gastroenteritis attributed to a viral pathogen. Clin Gastroenterol Hepatol 2007;5:457-460. (Pubitemid 46575359)
31. Soyturk M., Akpinar H., Gurler O., et al. Irritable bowel syndrome in persons who acquired trichinellosis. Am J Gastroenterol 2007;102:1064-1069. (Pubitemid 46698220)
32. Gonsalkorale W.M., Perrey C., Pravica V., Whorwell P.J., Hutchinson I.V. Interleukin 10 genotypes in irritable bowel syndrome: evidence for an inflammatory component? Gut 2003;52:91-93. (Pubitemid 36020772)
33. van der Veek P.P., van den Berg M., de Kroon Y.E., Verspaget H.W., Masclee A.A. Role of tumor necrosis factor-alpha and interleukin- 10 gene polymorphisms in irritable bowel syndrome. Am J Gastroenterol 2005;100:2510-2516.
34. Lin H.C. Small intestinal bacterial overgrowth: A framework for understanding irritable bowel syndrome. JAMA 2004;292:852-858. (Pubitemid 39079672)
35. Ford A.C., Spiegel B.M., Talley N.J., Moayyedi P. Small intestinal bacterial overgrowth in irritable bowel syndrome: systematic review and meta-analysis. Clin Gastroenterol Hepatol 2009;7:1279-1286.
36. Malinen E., Rinttilä T., Kajander K., et al. Analysis of the fecal microbiota of irritable bowel syndrome patients and healthy controls with real-time PCR. Am J Gastroenterol 2005;100:373-382. (Pubitemid 40314522)
37. Kassinen A., Krogius-Kurikka L., Mäkivuokko H., et al. The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects. Gastroenterology 2007;133:24-33. (Pubitemid 47031125)
38. Carroll I.M., Chang Y.H., Park J., Sartor R.B., Ringel Y. Luminal and mucosal-associated intestinal microbiota in patients with diarrhea-predominant irritable bowel syndrome. Gut Pathog 2010;2:19.
39. Kerckhoffs A.P., Ben-Amor K., Samsom M., et al. Molecular analysis of faecal and duodenal samples reveals significantly higher prevalence and numbers of Pseudomonas aeruginosa in irritable bowel syndrome. J Med Microbiol 2011;60(Pt 2):236-245.
40. Park M.I., Camilleri M. Genetics and genotypes in irritable bowel syndrome: implications for diagnosis and treatment. Gastroenterol Clin North Am 2005;34:305-317. (Pubitemid 40615958)
41. Nastaskin I., Mehdikhani E., Conklin J., Park S., Pimentel M. Studying the overlap between IBS and GERD: a systematic review of the literature. Dig Dis Sci 2006;51:2113-2120.
42. Ford A.C., Marwaha A., Lim A., Moayyedi P. Systematic review and meta-analysis of the prevalence of irritable bowel syndrome in individuals with dyspepsia. Clin Gastroenterol Hepatol 2010;8:401-409.
43. Lee S.Y., Lee K.J., Kim S.J., Cho S.W. Prevalence and risk factors for overlaps between gastroesophageal reflux disease, dyspepsia, and irritable bowel syndrome: a population-based study. Digestion 2009;79:196-201.
44. Kaji M., Fujiwara Y., Shiba M., et al. Prevalence of overlaps between GERD, FD and IBS and impact on health-related quality of life. J Gastroenterol Hepatol 2010;25:1151-1156.
45. De Vries D.R., Van Herwaarden M.A., Baron A., Smout A.J., Samsom M. Concomitant functional dyspepsia and irritable bowel syndrome decrease health-related quality of life in gastroesophageal reflux disease. Scand J Gastroenterol 2007;42:951-956. (Pubitemid 47037124)
46. Nojkov B., Rubenstein J.H., Adlis S.A., et al. The influence of co-morbid IBS and psychological distress on outcomes and quality of life following PPI therapy in patients with gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2008;27:473-482. (Pubitemid 351300853)
47. American College of Gastroenterology Task Force on Irritable Bowel Syndrome, Brandt LJ, Chey WD, et al. An evidence-based position statement on the management of irritable bowel syndrome. Am J Gastroenterol 2009;104 Suppl 1:S1-S35.
48. Stevens J., VanSoest P.J., Robertson J.B., Levitsky D.A. Comparison of the effects of psyllium and wheat bran on gastrointestinal transit time and stool characteristics. J Am Diet Assoc 1988;88:323-326. (Pubitemid 18085100)
49. Bijkerk C.J., De Wit N.J., Muris J.W., Whorwell P.J., Knottnerus J.A., Hoes A.W. Soluble or insoluble fibre in irritable bowel syndrome in primary care? Randomised placebo controlled trial. BMJ 2009;339:b3154.
50. Khoshoo V., Armstead C., Landry L. Effect of a laxative with and without tegaserod in adolescents with constipation predominant irritable bowel syndrome. Aliment Pharmacol Ther 2006;23:191-196. (Pubitemid 43381183)
51. Gershon M.D., Tack J. The serotonin signaling system: From basic understanding to drug development for functional GI disorders. Gastroenterology 2007;132:397-414. (Pubitemid 46127672)
52. Degen L., Petrig C., Studer D., Schroller S., Beglinger C. Effect of tegaserod on gut transit in male and female subjects. Neurogastroenterol Motil 2005;17:821-826. (Pubitemid 41746520)
53. Müller-Lissner S.A., Fumagalli I., Bardhan K.D., et al. Tegaserod, a 5-HT(4) receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation. Aliment Pharmacol Ther 2001;15:1655-1666. (Pubitemid 32912410)
54. Novick J., Miner P., Krause R., et al. A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation. Aliment Pharmacol Ther 2002;16:1877-1888.
55. Lefkowitz M., Shi Y., Heggland J., Dunger-Baldauf C., Ruegg P. Tegaserod rapidly improves abdominal pain, bloating and bowel function in patients with C-IBS. Gut 2000;47(Suppl 3):A217.
56. Chey W.D., Paré P., Viegas A., Ligozio G., Shetzline M.A. Tegaserod for female patients suffering from IBS with mixed bowel habits or constipation: A randomized controlled trial. Am J Gastroenterol 2008;103:1217-1225. (Pubitemid 351677994)
57. Kellow J., Lee O.Y., Chang F.Y., et al. An Asia-Pacific, double blind, placebo controlled, randomised study to evaluate the efficacy, safety, and tolerability of tegaserod in patients with irritable bowel syndrome. Gut 2003;52:671-676. (Pubitemid 36528868)
58. Nyhlin H., Bang C., Elsborg L., et al. A double-blind, placebo-controlled, randomized study to evaluate the efficacy, safety and tolerability of tegaserod in patients with irritable bowel syndrome. Scand J Gastroenterol 2004;39:119-126. (Pubitemid 38253623)
59. Tougas G., Snape W.J. Jr, Otten M.H., et al. Long-term safety of tegaserod in patients with constipation-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2002;16:1701-1708.
60. Thompson C.A. Novartis suspends tegaserod sales at FDA's request. Am J Health Syst Pharm 2007;64:1020. (Pubitemid 46801527)
61. Serebruany V.L., El Mouelhi M., Pfannkuche H.J., Rose K., Marro M., Angiolillo D.J. Investigations on 5-HT4 receptor expression and effects of tegaserod on human platelet aggregation in vitro. Am J Ther 2010;17:543-552.
62. Schoenfeld P. Review article: The safety profile of tegaserod. Aliment Pharmacol Ther 2004;20 Suppl 7:25-30. (Pubitemid 39657673)
63. Maneerattanaporn M., Chang L., Chey W.D. Emerging pharmacological therapies for the irritable bowel syndrome. Gastroenterol Clin North Am 2011;40:223-243.
64. Johanson J.F., Drossman D.A., Panas R., Wahle A., Ueno R. Clinical trial: Phase 2 study of lubiprostone for irritable bowel syndrome with constipation. Aliment Pharmacol Ther 2008;27:685-696. (Pubitemid 351406304)
65. Drossman D.A., Chey W.D., Johanson J.F., et al. Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome--results of two randomized, placebo-controlled studies. Aliment Pharmacol Ther 2009;29:329-341.
66. Lembo A.J., Kurtz C.B., Macdougall J.E., et al. Efficacy of linaclotide for patients with chronic constipation. Gastroenterology 2010;138:886-895.e1.
67. Lembo A., Schneier H., Lavins B.J., et al. 286 efficacy and safety of once daily linaclotide administered orally for 12-weeks in patients with chronic constipation: results from 2 randomized, double-blind, placebo-controlled phase 3 trials. Gastroenterology 2010;138(5 Suppl 1):S53-S54.
68. Ironwood and Forest announce positive linaclotide results from second phase 3 trial in patients with irritable bowel syndrome with constipation 2010 [Internet]. Forest Laboratories, Inc. & Ironwood Pharmaceuticals, Inc.; 2010 [cited 2010 Dec 2]. Available from: http://www.ironwoodpharma.com/newsPDF/IRWD. FRX.Ph3.MCP-103-302.11.01.10.pdf.
69. Shailubhai K., Talluto C., Comiskey S., Foss J., Joslyn A., Jacob G. Phase II clinical evaluation of SP-304, a guanylate cyclase-C agonist, for treatment of chronic constipation. Am J Gastroenterol 2010;105:S487-S488.
70. Rao A.S., Wong B.S., Camilleri M., et al. Chenodeoxycholate in females with irritable bowel syndrome-constipation: a pharmacodynamic and pharmacogenetic analysis. Gastroenterology 2010;139:1549-1558, 1558.e1.
71. Chey W.D., Camilleri M., Chang L., Rikner L., Graffner H. A3309, an ileal bile acid transport (IBAT/ASBT) inhibitor, significantly improved stool frequency and other constipation-related complaints in adults with chronic constipation: data from an 8-week, randomized, double-blind, placebo-controlled study. Gastroenterology 2011;140(5 Suppl 1):S3.
72. Cann P.A., Read N.W., Holdsworth C.D., Barends D. Role of loperamide and placebo in management of irritable bowel syndrome (IBS). Dig Dis Sci 1984;29:239-247. (Pubitemid 14158881)
73. Hovdenak N. Loperamide treatment of the irritable bowel syndrome. Scand J Gastroenterol Suppl 1987;130:81-84. (Pubitemid 17112890)
74. Lavö B., Stenstam M., Nielsen A.L. Loperamide in treatment of irritable bowel syndrome: A double-blind placebo controlled study. Scand J Gastroenterol Suppl 1987;130:77-80. (Pubitemid 17112889)
75. Efskind P.S., Bernklev T., Vatn M.H. A double-blind placebo-controlled trial with loperamide in irritable bowel syndrome. Scand J Gastroenterol 1996;31:463-468. (Pubitemid 26153637)
76. Talley N.J., Phillips S.F., Haddad A., et al. GR 38032F (ondansetron), a selective 5HT3 receptor antagonist, slows colonic transit in healthy man. Dig Dis Sci 1990;35:477-480. (Pubitemid 20116748)
77. Zighelboim J., Talley N.J., Phillips S.F., Harmsen W.S., Zinsmeister A.R. Visceral perception in irritable bowel syndrome. Rectal and gastric responses to distension and serotonin type 3 antagonism. Dig Dis Sci 1995;40:819-827.
78. Delvaux M., Louvel D., Mamet J.P., Campos-Oriola R., Frexinos J. Effect of alosetron on responses to colonic distension in patients with irritable bowel syndrome. Aliment Pharmacol Ther 1998;12:849-855. (Pubitemid 28428949)
79. Houghton L.A., Foster J.M., Whorwell P.J. Alosetron, a 5-HT3 receptor antagonist, delays colonic transit in patients with irritable bowel syndrome and healthy volunteers. Aliment Pharmacol Ther 2000;14:775-782. (Pubitemid 30352745)
80. Camilleri M., Northcutt A.R., Kong S., Dukes G.E., McSorley D., Mangel A.W. Efficacy and safety of alosetron in women with irritable bowel syndrome: A randomised, placebo-controlled trial. Lancet 2000;355:1035-1040. (Pubitemid 30162805)
81. Camilleri M., Chey W.Y., Mayer E.A., et al. A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome. Arch Intern Med 2001;161:1733-1740. (Pubitemid 32679548)
82. Watson M.E., Lacey L., Kong S., et al. Alosetron improves quality of life in women with diarrhea-predominant irritable bowel syndrome. Am J Gastroenterol 2001;96:455-459.
83. Lembo T., Wright R.A., Bagby B., et al. Alosetron controls bowel urgency and provides global symptom improvement in women with diarrhea-predominant irritable bowel syndrome. Am J Gastroenterol 2001;96:2662-2670.
84. Chey W.D., Chey W.Y., Heath A.T., et al. Long-term safety and efficacy of alosetron in women with severe diarrhea-predominant irritable bowel syndrome. Am J Gastroenterol 2004;99:2195-2203. (Pubitemid 39524711)
85. Chang L., Ameen V.Z., Dukes G.E., McSorley D.J., Carter E.G., Mayer E.A. A dose-ranging, phase II study of the efficacy and safety of alosetron in men with diarrhea-predominant IBS. Am J Gastroenterol 2005;100:115-123. (Pubitemid 41623278)
86. Chang L., Chey W.D., Harris L., Olden K., Surawicz C., Schoenfeld P. Incidence of ischemic colitis and serious complications of constipation among patients using alosetron: Systematic review of clinical trials and post-marketing surveillance data. Am J Gastroenterol 2006;101:1069-1079. (Pubitemid 43725322)
87. Ford A.C., Brandt L.J., Young C., Chey W.D., Foxx-Orenstein A.E., Moayyedi P. Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: systematic review and meta-analysis. Am J Gastroenterol 2009;104:1831-1843.
88. Matsueda K., Harasawa S., Hongo M., Hiwatashi N., Sasaki D. A phase II trial of the novel serotonin type 3 receptor antagonist ramosetron in Japanese male and female patients with diarrhea-predominant irritable bowel syndrome. Digestion 2008;77:225-235.
89. Frissora C.L., Cash B.D. Review article: The role of antibiotics vs. conventional pharmacotherapy in treating symptoms of irritable bowel syndrome. Aliment Pharmacol Ther 2007;25:1271-1281. (Pubitemid 46763454)
90. Lembo A., Zakko S.F., Ferreira N.L., et al. T1390 rifaximin for the treatment of diarrhea-associated irritable bowel syndrome: short term treatment leading to long term sustained response. Gastroenterology 2008;134(4 Suppl 1):A545.
91. Pimentel M., Lembo A., Chey W.D., et al. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med 2011;364:22-32.
92. Pimentel M., Park S., Mirocha J., Kane S.V., Kong Y. The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: A randomized trial. Ann Intern Med 2006;145:557-563. (Pubitemid 46780934)
93. Tack J. Antibiotic therapy for the irritable bowel syndrome. N Engl J Med 2011;364:81-82.
94. Lauritano E.C., Gabrielli M., Scarpellini E., et al. Small intestinal bacterial overgrowth recurrence after antibiotic therapy. Am J Gastroenterol 2008;103:2031-2035.
95. Camilleri M. Novel pharmacology: asimadoline, a kappa-opioid agonist, and visceral sensation. Neurogastroenterol Motil 2008;20:971-979.
96. Mangel A.W., Bornstein J.D., Hamm L.R., et al. Clinical trial: asimadoline in the treatment of patients with irritable bowel syndrome. Aliment Pharmacol Ther 2008;28:239-249. (Pubitemid 351861967)
97. Tack J.F., Harris M.S., Proksch S., Bornstein J.D., Miner P.B. S1298 AST-120 (spherical carbon adsorbent) improves pain and bloating in a randomized, double-blind, placebo-controlled trial in patients with non-constipating irritable bowel syndrome (IBS). Gastroenterology 2010;138(5 Suppl 1):S223.
98. Sweetser S., Camilleri M., Linker Nord S.J., et al. Do corticotropin releasing factor-1 receptors influence colonic transit and bowel function in women with irritable bowel syndrome? Am J Physiol Gastrointest Liver Physiol 2009;296:G1299-G1306.
99. Dukes G.E., Mayer E.A., Kelleher D.L., Hicks K.J., Boardley R.L., Alpers D.H. A randomised, double blind, placebo controlled, crossover study to evaluate the efficacy and safety of the CRF1 receptor antagonist GW876008 in irritable bowel syndrome patients. Neurogastroenterol Motil 2009;21(Suppl):84.
100. Mangel A.W., Chaturvedi P. Evaluation of crofelemer in the treatment of diarrhea-predominant irritable bowel syndrome patients. Digestion 2008;78:180-186.
101. Leventer S.M., Raudibaugh K., Frissora C.L., et al. Clinical trial: Dextofisopam in the treatment of patients with diarrhoea-predominant or alternating irritable bowel syndrome. Aliment Pharmacol Ther 2008;27:197-206. (Pubitemid 350256611)
102. Brown P., Riff D.S., Jackson J., et al. 907 LX1031, a novel locally-acting inhibitor of serotonin (5-HT) synthesis significantly improves symptoms in patients with IBS. Gastroenterology 2010;138(5 Suppl 1):S129.
103. Talley N.J. Pharmacologic therapy for the irritable bowel syndrome. Am J Gastroenterol 2003;98:750-758. (Pubitemid 36576297)
104. Darvish-Damavandi M., Nikfar S., Abdollahi M. A systematic review of efficacy and tolerability of mebeverine in irritable bowel syndrome. World J Gastroenterol 2010;16:547-553.
105. Poynard T., Regimbeau C., Benhamou Y. Meta-analysis of smooth muscle relaxants in The treatment of irritable bowel syndrome. Aliment Pharmacol Ther 2001;15:355-361. (Pubitemid 32187557)
106. Jailwala J., Imperiale T.F., Kroenke K. Pharmacologic treatment of the irritable bowel syndrome: A systematic review of randomized, controlled trials. Ann Intern Med 2000;133:136-147. (Pubitemid 30490414)
107. Goulding M.R. Inappropriate medication prescribing for elderly ambulatory care patients. Arch Intern Med 2004;164:305-312. (Pubitemid 38176470)
108. Ford A.C., Talley N.J., Schoenfeld P.S., Quigley E.M., Moayyedi P. Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis. Gut 2009;58:367-378.
109. Lesbros-Pantoflickova D., Michetti P., Fried M., Beglinger C., Blum A.L. Meta-analysis: the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 2004;20:1253-1269. (Pubitemid 40040072)
110. Gorard D.A., Libby G.W., Farthing M.J. Influence of antidepressants on whole gut and orocaecal transit times in health and irritable bowel syndrome. Aliment Pharmacol Ther 1994;8:159-166. (Pubitemid 24220591)
111. Brennan B.P., Fogarty K.V., Roberts J.L., Reynolds K.A., Pope H.G. Jr, Hudson J.I. Duloxetine in the treatment of irritable bowel syndrome: an open-label pilot study. Hum Psychopharmacol 2009;24:423-428.
112. Chial H.J., Camilleri M., Ferber I., et al. Effects of venlafaxine, buspirone, and placebo on colonic sensorimotor functions in healthy humans. Clin Gastroenterol Hepatol 2003;1:211-218. (Pubitemid 37248072)
113. Kong S.C., Hurlstone D.P., Pocock C.Y., et al. The Incidence of self-prescribed oral complementary and alternative medicine use by patients with gastrointestinal diseases. J Clin Gastroenterol 2005;39:138-141. (Pubitemid 40130027)
114. van Tilburg M.A., Palsson O.S., Levy R.L., et al. Complementary and alternative medicine use and cost in functional bowel disorders: a six month prospective study in a large HMO. BMC Complement Altern Med 2008;8:46.
115. Borowiec A.M., Fedorak R.N. The role of probiotics in management of irritable bowel syndrome. Curr Gastroenterol Rep 2007;9:393-400.
116. Moayyedi P., Ford A.C., Talley N.J., et al. The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review. Gut 2010;59:325-332.
117. Brenner D.M., Moeller M.J., Chey W.D., Schoenfeld P.S. The utility of probiotics in the treatment of irritable bowel syndrome: a systematic review. Am J Gastroenterol 2009;104:1033-1049.
118. O'Mahony L., McCarthy J., Kelly P., et al. Lactobacillus and bifidobacterium in irritable bowel syndrome: Symptom responses and relationship to cytokine profiles. Gastroenterology 2005;128:541-551. (Pubitemid 40585355)
119. Whorwell P.J., Altringer L., Morel J., et al. Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Am J Gastroenterol 2006;101:1581-1590. (Pubitemid 43980633)
120. Bian Z., Wu T., Liu L., et al. Effectiveness of the Chinese herbal formula TongXieYaoFang for irritable bowel syndrome: A systematic review. J Altern Complement Med 2006;12:401-407. (Pubitemid 43807599)
121. Hills J.M., Aaronson P.I. The mechanism of action of peppermint oil on gastrointestinal smooth muscle: an analysis using patch clamp electrophysiology and isolated tissue pharmacology in rabbit and guinea pig. Gastroenterology 1991;101:55-65.
122. Hawthorn M., Ferrante J., Luchowski E., Rutledge A., Wei X.Y., Triggle D.J. The actions of peppermint oil and menthol on calcium channel dependent processes in intestinal, neuronal and cardiac preparations. Aliment Pharmacol Ther 1988;2:101-118.
123. Pittler M.H., Ernst E. Peppermint oil for irritable bowel syndrome: A critical review and metaanalysis. Am J Gastroenterol 1998;93:1131-1135. (Pubitemid 29080964)
124. Spanier J.A., Howden C.W., Jones M.P. A systematic review of alternative therapies in the irritable bowel syndrome. Arch Intern Med 2003;163:265-274. (Pubitemid 36183854)
125. Ford A.C., Talley N.J., Spiegel B.M., et al. Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis. BMJ 2008;337:a2313.
126. Merat S., Khalili S., Mostajabi P., Ghorbani A., Ansari R., Malekzadeh R. The effect of enteric-coated, delayed-release peppermint oil on irritable bowel syndrome. Dig Dis Sci 2010;55:1385-1390.
127. Bensoussan A., Talley N.J., Hing M., Menzies R., Guo A., Ngu M. Treatment of irritable bowel syndrome with Chinese herbal medicine: A randomized controlled trial. JAMA 1998;280:1585-1589. (Pubitemid 28520646)
128. Liu J.P., Yang M., Liu Y.X., Wei M.L., Grimsgaard S. Herbal medicines for treatment of irritable bowel syndrome. Cochrane Database Syst Rev 2006;(1):CD004116.
129. Saito Y.A., Rey E., Almazar-Elder A.E., et al. A randomized, double-blind, placebo-controlled trial of St John's wort for treating irritable bowel syndrome. Am J Gastroenterol 2010;105:170-177.
130. Fireman Z., Segal A., Kopelman Y., Sternberg A., Carasso R. Acupuncture treatment for irritable bowel syndrome: A double-blind controlled study. Digestion 2001;64:100-103. (Pubitemid 34701877)
131. Forbes A., Jackson S., Walter C., Quraishi S., Jacyna M., Pitcher M. Acupuncture for irritable bowel syndrome: A blinded placebo-controlled trial. World J Gastroenterol 2005;11:4040-4044. (Pubitemid 41235601)
132. Schneider A., Enck P., Streitberger K., et al. Acupuncture treatment in irritable bowel syndrome. Gut 2006;55:649-654.
133. Lembo A.J., Conboy L., Kelley J.M., et al. A treatment trial of acupuncture in IBS patients. Am J Gastroenterol 2009;104:1489-1497.
134. Saito Y.A., Schoenfeld P., Locke G.R. 3rd. The epidemiology of irritable bowel syndrome in North America: a systematic review. Am J Gastroenterol 2002;97:1910-1915.
135. Talley N.J., Zinsmeister A.R., Melton L.J. 3rd. Irritable bowel syndrome in a community: symptom subgroups, risk factors, and health care utilization. Am J Epidemiol 1995;142:76-83.
136. Talley N.J., Zinsmeister A.R., Van Dyke C., Melton L.J. 3rd. Epidemiology of colonic symptoms and the irritable bowel syndrome. Gastroenterology 1991;101:927-934.
137. Guilera M., Balboa A., Mearin F. Bowel habit subtypes and temporal patterns in irritable bowel syndrome: systematic review. Am J Gastroenterol 2005;100:1174-1184. (Pubitemid 40769059)
138. Systematic review on the management of irritable bowel syndrome in the European Union. Eur J Gastroenterol Hepatol 2007;19 Suppl 1:S11-S37.
139. Gwee K.A., Bak Y.T., Ghoshal U.C., et al. Asian consensus on irritable bowel syndrome. J Gastroenterol Hepatol 2010;25:1189-1205.
140. Gwee K.A., Lu C.L., Ghoshal U.C. Epidemiology of irritable bowel syndrome in Asia: something old, something new, something borrowed. J Gastroenterol Hepatol 2009;24:1601-1607.